As the pharmaceutical industry shifts toward patient-centered, data-driven innovation, Real-World Evidence has become a critical pillar in oncology research and market access strategy. At our Centre for Observational and Real-World Evidence (CORE), we leverage real-world data to complement clinical trial findings, offering a fuller picture of how our anticancer therapies perform in routine clinical settings. This presentation will explore how oncology-focused RWE informs internal R&D, strengthens the value proposition for health technology assessments (HTAs), and enhances scientific engagement with key stakeholders. We will address the growing complexity of HTA requirements, the evidentiary expectations for market access, and how collaborative, transparent communication across scientific and regulatory communities can overcome these challenges. In this session, you will learn:

• How to integrate real-world oncology data into early research and development to inform future therapeutic strategies.
• How to address and align with evolving HTA requirements using real-world evidence.
• How to optimize scientific engagement with stakeholders through effective communication of real-world insights.